Early control treatment with montelukast in preschool children with asthma: A randomized controlled trial.

Mizuho Nagao, Masanori Ikeda, Norimasa Fukuda, Chizu Habukawa, Tetsuro Kitamura, Toshio Katsunuma, Takao Fujisawa

Journal: Allergology international : official journal of the Japanese Society of Allergology 2018;67(1):72-78

PMID: 28526210

Abstract

BACKGROUND

While Japanese guideline recommends initial control treatment for preschool children with asthma symptoms more than once a month, Western guidelines do not. To determine whether control treatment with montelukast was more effective than as-needed β-agonists in this population, we conducted a randomized controlled trial.

METHODS

Eligible patients were children aged 1-5 years who had asthma symptoms more than once a month but less than once a week. Patients were randomly assigned in a 1:1 ratio to receive montelukast 4 mg daily for 48 weeks or as-needed β-agonists. The primary endpoint was the number of acute asthma exacerbations before starting step-up treatment with inhaled corticosteroids. This study is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000002219.

RESULTS

From September 2009 to November 2012, 93 patients (47 in the montelukast group and 46 in the no-controller group) were enrolled into the study. All patients were included in the analysis. During the study, 13 patients (28%) in the montelukast group and 23 patients (50%) in the no-controller group had acute exacerbations with the mean numbers of 0.9 and 1.9/year, respectively (P = 0.027). In addition, 10 (21%) and 19 (41%) patients received step-up treatment, respectively. Cumulative incidence of step-up treatment was significantly lower in the montelukast group (hazard ratio 0.45, 95% confidence interval 0.21 to 0.92; P = 0.033).

CONCLUSIONS

Montelukast is an effective control treatment for preschool children who had asthma symptoms more than once a month but less than once a week.

Copyright © 2017 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.

Address: Allergy Center, Mie National Hospital, Tsu, Japan.; Department of Pediatrics, Fukuyama Medical Center, Fukuyama, Japan.; Grimm Pediatric Clinic, Shimotsuke, Japan.; Department of Pediatrics, Minami Wakayama Medical Center, Tanabe, Japan.; Department of Pediatrics, Nippon Kokan Fukuyama Hospital, Fukuyama, Japan.; Department of Pediatrics, Tsunan Hospital, Tsunan, Japan; Department of Pediatrics, Jikei University Daisan Hospital, Tokyo, Japan.; Allergy Center, Mie National Hospital, Tsu, Japan. Electronic address: [email protected].; Saitama Medical Univeristy, Japan.; Terada Allergy and Pediatric Clinic, Japan.; Shimoshizu National Hospital, Japan.; Miyagi Prefectural Children's Hospital, Japan.; Gunma University, Japan.; Saga University, Japan.; Chukyo University, Japan.; Kanagawa Prefectural Children's Medical Center, Japan.; Chiba University, Japan.; Osaka Prefectural Respiratory and Allergy Medical Center, Japan.; Tokai University, Japan.; Jikei University, Japan.; Doai Fraternal Hospital, Japan.; Toyama University, Japan.; University of Fukui, Japan.; Dokkyo Medical University, Japan.; Kurashiki Center Hospital, Japan.; Rokko Island Hospital, Japan.; Smile Kids Clinic, Japan.; Tokuda Family Clinic, Japan.; Shinko Hospital, Japan.; Araki Pediatric Clinic, Japan.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.